Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.
Scheltens P, Atri A, Feldman HH, Zetterberg H, Sano M, Johannsen P, Colombo TL, Bardtrum L, Jeppesen R, Hansen CT, Cummings JL.
Scheltens P, et al.
Alzheimers Dement (N Y). 2026 Jan 10;12(1):e70200. doi: 10.1002/trc2.70200. eCollection 2026 Jan-Mar.
Alzheimers Dement (N Y). 2026.
PMID: 41522368
Free PMC article.
METHODS: Evoke (+) are two ongoing global, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 trials investigating semaglutide in participants with early-stage symptomatic Alzheimer's disease (AD) with confirmed amyloid positivity (by positron emiss …
METHODS: Evoke (+) are two ongoing global, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 trials investig …